THE DE-ESCALATE STUDY: ATAZANAVIR OR ATAZANAVIR/RITONAVIR SUBSTITUTION IN HIV

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这是一项随机、对照、初步研究，旨在比较Atazanavir（ATV）或ATV/利托那韦（RTV）替代利托那韦加强蛋白抑制剂（PI）治疗正在发生高脂血症和/或需要降脂药物治疗的持续病毒血症患者的安全性和疗效。 在本研究中，60例正在接受利托那韦加强的含PI抗逆转录病毒治疗方案的受试者将以1：1：1的比例随机分配，将抗逆转录病毒治疗方案中利托那韦加强的PI组分转换为ATV或ATV/RTV，或继续利托那韦加强的基于PI的治疗方案。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a randomized, controlled, pilot study to compare the safety and efficacy of substitution of Atazanavir (ATV) or ATV/Ritonavir (RTV) for Ritonavir boosted protein inhibitor (PI) in patients with ongoing viremia who are experiencing hyperlipidemia and/or requiring treatment with lipid lowering agents. In this study, 60 subjects on a Ritonavir-boosted PI-containing antiretroviral regimen who are experiencing hyperlipidemia and ongoing HIV viremia will be randomized in a 1:1:1 ratio to either switch the Ritonavir-boosted PI component of the antiretroviral regimen to ATV or ATV/RTV, or continue the Ritonavir-boosted PI-based regimen.